Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003901
Status:
COMPLETED
Last Update Posted:
2017-02-16
First Post:
1999-11-01
Brief Title:
Prognostic Study of Metastases in Patients With Stage I Stage II or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Prognostic testing for early signs of metastases may help doctors detect metastases early and plan more effective treatment
PURPOSE Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I stage II or stage III non-small cell lung cancer that can be removed by surgery
PURPOSE Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I stage II or stage III non-small cell lung cancer that can be removed by surgery
Detailed Description:
OBJECTIVES
Determine the relationship between three indicators of occult metastases cytological examination of pleural lavage immunohistochemistry IHC assay of lymph nodes and IHC assay of rib bone marrow and survival of patients with resectable non-small cell lung cancer
Determine the relationship between these indicators and conventional histology
Model survival considering the indicators and other patient attributes that are of prime prognostic significance
Determine the relationships between the indicators and the site of first recurrence in these patients
Determine the prevalence of the indicators in these patients
Determine the relationships between the indicators and disease free survival in these patients
Determine the relationship between three indicators of occult metastases cytological examination of pleural lavage immunohistochemistry IHC assay of lymph nodes and IHC assay of rib bone marrow and survival of patients with resectable non-small cell lung cancer
Determine the relationship between these indicators and conventional histology
Model survival considering the indicators and other patient attributes that are of prime prognostic significance
Determine the relationships between the indicators and the site of first recurrence in these patients
Determine the prevalence of the indicators in these patients
Determine the relationships between the indicators and disease free survival in these patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067072 | REGISTRY | NCI Physician Data Query | None |